Combining Tests Leads to Better Prediabetes Detection
By LabMedica International staff writers Posted on 16 Dec 2015 |

Image: Steps in the oral glucose tolerance test; if the blood sugar level is 140 to 199 mg/dL, the person has prediabetes or impaired glucose tolerance (IGT) (Photo courtesy of Penn Medicine).
The application of a screening test that is both robust and handy is vital for promptly ascertaining subjects with prediabetes. A robust and quick prediabetes diagnostic test can reduce overall societal costs of diabetes by motivating subjects with prediabetes to seek diabetes preventative care.
Fasting plasma glucose (FPG) and oral glucose tolerance (OGT) tests are greatly used in screening and diagnosing type 2 diabetes and while the OGT test is mostly recognized as the benchmark for diagnosing type 2 diabetes, but the test is laborious and uncomfortable to patients.
Scientists at Georgia State University (Atlanta, GA, USA) studied a group of participants whose ages ranged from 12 to 75 years with no missing values for age, height, weight, and assayed for OGT, FPG and HbA1c. Subjects were categorized as nondiabetic if they had FPG of less than 25 mg/dL or FPG of less than 199 mg/dL on a two-hour OGT test and HbA1c less than 6.5%. Prediabetes comprises impaired fasting glucose (IFG) expressed as FPG 100–125 mg/dL, impaired glucose tolerance (IGT) as OGT of 140–199 mg/dL, and HbA1c 5.7–6.4%.
The scientists found that the joint use of FPG and HbA1c test was associated with significantly higher proportion of subjects with prediabetes across age, race/ethnicity and BMI as compared to combined use of OGT and FPG, OGT and HbA1c. Overall prevalence of prediabetes using OGT + FPG, OGT + HbA1c, HbA1c + FPG, and OGT + FPG + HbA1c tests were 20.3%, 24.2%, 33%, and 34.3%, respectively. The study indicates prediabetes rates were higher using HbA1c + FPG tests compared to the traditionally used OGT + FPG tests.
The authors concluded that using a combination of HbA1c and FPG test in screening for prediabetes provides the benefits of individual test and decreases the risk of systematic bias inherent in using only HbA1c testing. This study proposes the need to redefine a basic and a practical way on the application of HbA1cin screening for prediabetes. The use of HbA1c test in detection of prediabetes in population and clinical settings should take into account patient race/ethnicity, gender, age, and body mass index (BMI). The study was published November 20, 2015, in the journal Frontiers in Public Health.
Related Links:
Georgia State University
Fasting plasma glucose (FPG) and oral glucose tolerance (OGT) tests are greatly used in screening and diagnosing type 2 diabetes and while the OGT test is mostly recognized as the benchmark for diagnosing type 2 diabetes, but the test is laborious and uncomfortable to patients.
Scientists at Georgia State University (Atlanta, GA, USA) studied a group of participants whose ages ranged from 12 to 75 years with no missing values for age, height, weight, and assayed for OGT, FPG and HbA1c. Subjects were categorized as nondiabetic if they had FPG of less than 25 mg/dL or FPG of less than 199 mg/dL on a two-hour OGT test and HbA1c less than 6.5%. Prediabetes comprises impaired fasting glucose (IFG) expressed as FPG 100–125 mg/dL, impaired glucose tolerance (IGT) as OGT of 140–199 mg/dL, and HbA1c 5.7–6.4%.
The scientists found that the joint use of FPG and HbA1c test was associated with significantly higher proportion of subjects with prediabetes across age, race/ethnicity and BMI as compared to combined use of OGT and FPG, OGT and HbA1c. Overall prevalence of prediabetes using OGT + FPG, OGT + HbA1c, HbA1c + FPG, and OGT + FPG + HbA1c tests were 20.3%, 24.2%, 33%, and 34.3%, respectively. The study indicates prediabetes rates were higher using HbA1c + FPG tests compared to the traditionally used OGT + FPG tests.
The authors concluded that using a combination of HbA1c and FPG test in screening for prediabetes provides the benefits of individual test and decreases the risk of systematic bias inherent in using only HbA1c testing. This study proposes the need to redefine a basic and a practical way on the application of HbA1cin screening for prediabetes. The use of HbA1c test in detection of prediabetes in population and clinical settings should take into account patient race/ethnicity, gender, age, and body mass index (BMI). The study was published November 20, 2015, in the journal Frontiers in Public Health.
Related Links:
Georgia State University
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more